Drug intelligence / Profile preview

Ad26.RSV.FA2 + Ad35.RSV.FA2

Development stage: Preclinical
Lead developer: Janssen Pharmaceutical
Modality: Gene Therapies, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Ad26.RSV.FA2 + Ad35.RSV.FA2 is an investigational combination vaccine candidate for the prevention of respiratory syncytial virus (RSV) infection. The vaccine comprises two non-replicating adenoviral vectors: Ad26.RSV.FA2 and Ad35.RSV.FA2, both designed to express the RSV F (fusion) protein antigen. Adenoviral vectors (serotypes 26 and 35) serve as platforms to induce robust humoral and cellular immune responses against RSV by delivering the gene encoding the prefusion RSV F protein to host cells, which then express the antigen and stimulate immunity. The approach aims to leverage the immunogenic potential of two distinct adenoviral backbones to reduce vector-specific immune interference and optimize the immune response to RSV. This combination is developed primarily for prophylactic use against RSV in populations at risk.

Other names: Ad35.RSV.FA2 + Ad26.RSV.FA2

Targets

RSV preF (Respiratory syncytial virus prefusion F glycoprotein)

Beyond the preview

Go deeper on Ad26.RSV.FA2 + Ad35.RSV.FA2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ad26.RSV.FA2 + Ad35.RSV.FA2.

Explore the full profile